These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2491882)

  • 1. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer.
    Kavanagh JJ; Roberts W; Townsend P; Hewitt S
    J Clin Oncol; 1989 Jan; 7(1):115-8. PubMed ID: 2491882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer.
    Harvey HA; Lipton A; Max DT; Pearlman HG; Diaz-Perches R; de la Garza J
    J Clin Oncol; 1985 Aug; 3(8):1068-72. PubMed ID: 3926958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.
    Bruckner HW; Motwani BT
    Am J Obstet Gynecol; 1989 Nov; 161(5):1216-8. PubMed ID: 2511761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.
    Miller DS; Brady MF; Barrett RJ
    Am J Clin Oncol; 1992 Apr; 15(2):125-8. PubMed ID: 1553899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
    Smith JA
    J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of a persistent cyst, developing after ovarian transposition, with leuprolide acetate.
    Jarrell MA; Brumsted JR
    Obstet Gynecol; 1990 Nov; 76(5 Pt 2):927-8. PubMed ID: 2120646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor.
    Fishman A; Kudelka AP; Tresukosol D; Edwards CL; Freedman RS; Kaplan AL; Girtanner RE; Kavanagh JJ
    J Reprod Med; 1996 Jun; 41(6):393-6. PubMed ID: 8799913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group.
    Dlugi AM; Miller JD; Knittle J
    Fertil Steril; 1990 Sep; 54(3):419-27. PubMed ID: 2118858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
    Leuprolide Study Group
    N Engl J Med; 1984 Nov; 311(20):1281-6. PubMed ID: 6436700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leuprolide acetate in advanced ovarian serous tumor of low malignant potential. A case report.
    Tresukosol D; Kudelka AP; Edwards CL; Silva EG; Kanojia M; Kavanagh JJ
    J Reprod Med; 1996 May; 41(5):363-6. PubMed ID: 8725765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri.
    Friedman AJ; Barbieri RL; Doubilet PM; Fine C; Schiff I
    Fertil Steril; 1988 Mar; 49(3):404-9. PubMed ID: 2963759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer.
    Bourdin S; Karam G; Clemain P; Bouchot O; Peuvrel P; Lacoste J; Auvigne J
    J Int Med Res; 1990; 18 Suppl 1():74-8. PubMed ID: 2108888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
    N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotrophin hormone releasing analogues open new doors in cancer treatment.
    Waxman J
    Br Med J (Clin Res Ed); 1987 Oct; 295(6606):1084-5. PubMed ID: 2961401
    [No Abstract]   [Full Text] [Related]  

  • 17. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.
    Garnick MB
    Urology; 1986 Jan; 27(1 Suppl):21-8. PubMed ID: 3079935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium.
    Thompson MA; Adelson MD; Kaufman LM
    J Clin Endocrinol Metab; 1991 May; 72(5):1036-41. PubMed ID: 1902482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 20. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract; 1985 Feb; 39(2):73-6. PubMed ID: 3921047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.